The antileishmanial activity of novel oxygenated chalcones and their mechanism of action
about
Promising therapeutic targets for antileishmanial drugs.A lupane-triterpene isolated from Combretum leprosum Mart. fruit extracts that interferes with the intracellular development of Leishmania (L.) amazonensis in vitro.Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos.Investigational drugs for visceral leishmaniasis.Conformation analysis of a novel fluorinated chalcone.The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases.Aurapten, a coumarin with growth inhibition against Leishmania major promastigotes.Activity of synthetic chalcones in hamsters experimentally infected with Leishmania (Viannia) braziliensis.Synthesis and antileishmanial activity of novel pyridinium-hydrazone derivatives.Molecular dynamics of (E)-6-acetyl-3-(2-hydroxy-5-methylphenyl)-5-styryl cyclohex-2-en-1-one and (E)-6-ethylcarboxylate-3-(2-hydroxy-5-methylphenyl)-5-styryl cyclohex-2-en-1-one in a solution studied by NMR spectroscopy.1,1-Diphenyl,2-picrylhydrazyl free radical scavenging, bactericidal, fungicidal and leishmanicidal properties of Teucrium stocksianum.An Isoxazole Chalcone Derivative Enhances Melanogenesis in B16 Melanoma Cells via the Akt/GSK3β/β-Catenin Signaling Pathways.In vitro biotransformation, in vivo efficacy and pharmacokinetics of antimalarial chalcones.Antileishmanial, DNA Interaction, and Docking Studies of Some Ferrocene-Based Heteroleptic Pentavalent Antimonials.Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A.Contribution of Natural Products to Drug Discovery in Tropical DiseasesFocus on PAINS: false friends in the quest for selective anti-protozoal lead structures from Nature?
P2860
Q34837180-A9CB5761-EC19-4A2F-8D29-C692F4FE5890Q35655177-69D0929B-E4EE-4C29-AB75-9C34EEDFC1CFQ38154629-12E19D70-FB97-4E58-8C02-A59578782CB6Q38269581-3A71A667-FAD3-4A64-A56C-FE3FEB2DA593Q38933613-51E4050D-AE5E-4C28-9E48-C041ACAB2660Q38943630-220AA070-57EC-482C-A83A-663E1A160FECQ39293708-7404F358-6010-43E3-BA10-2700A73CD2CAQ41147459-92AF0F70-AE10-4FE8-8EA4-7ED1C373979CQ43870605-A961E423-6821-4E9B-B0AD-0EFA506EC614Q45185053-71E26CE0-EFD9-462F-8D1A-AB452A83762CQ46815708-400EEAA0-0AD0-4E35-B444-A04EE935189CQ47306701-63986702-8ACE-4C2C-8577-86FC5492DBB1Q47971086-4E016B09-8301-49E1-87A3-E6F6830AED7EQ53256666-50134F3B-3C79-4D04-B5AE-EFC35BF47F7DQ54421689-4176947B-35AC-4BEB-84A0-A140FE96A35AQ58854227-59B424FD-F880-42B8-9EB4-CEEC0EE2C972Q58856163-8BEA327A-2BEA-4364-B13A-DC7A831A97CC
P2860
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action
description
im Juni 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 June 1999
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 1999
@uk
name
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action
@en
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action
@nl
type
label
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action
@en
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action
@nl
prefLabel
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action
@en
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action
@nl
P2093
P2860
P356
P1476
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action
@en
P2093
P2860
P304
P356
10.1093/JAC/43.6.793
P407
P577
1999-06-01T00:00:00Z